| P/E (FY) | 10.1 | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | 11.33% |
| Net Margin | 22.03% | ROIC | 13.16% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 25.61% |
Bavarian Nordic develops, manufactures, and supplies vaccines. Its products include non-replicating smallpox and monkeypox vaccines sold as IMVAMUNE, IMVANEX, and JYNNEOS; rabies vaccine (Rabipur/RabAvert); tick-borne encephalitis vaccine (Encepur); the oral cholera vaccine Vaxchora; and the oral typhoid vaccine Vivotif/Typhoral. It is also developing MVA-BN WEV, in Phase 2 for encephalitis viruses. The company operates internationally and is headquartered in Hellerup, Denmark.
| Market Cap | — | Trading Days | 4011 |
| 52W High | 244.80 |
| 52W Low | 171.30 |
| % Off High | −27.12% |
| YTD | −6.52% | 1Y | −25.10% |
| 3Y | 24.06% | 5Y | −29.40% |
| 10Y | −10.69% | Since incept. (ann.) | 5.45% |
| Ann. Volatility (1Y) | 30.64% | Ann. Volatility (3Y) | 47.89% |
| Sharpe (1Y) | −0.81 | Sharpe (3Y) | 0.40 |
| Max Drawdown (1Y) | −28.75% | Max Drawdown (3Y) | −50.56% |
| Beta (3Y, vs SPY) | 0.98 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.14T | 52.7 |
| JNJ | JOHNSON & JOHNSON | $639.90B | 24.1 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| AMGN | AMGEN INC | $209.21B | 27.2 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| GILD | GILEAD SCIENCES, INC. | $164.79B | 19.6 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| SYK | STRYKER CORP | $135.04B | 41.9 |
| BMY | BRISTOL MYERS SQUIBB CO | $128.85B | 18.2 |
| ISRG | INTUITIVE SURGICAL INC | $124.74B | 44.9 |
